Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists.

Libert N, Tourtier JP, Védrine L, Chargari C.

Anesthesiology. 2010 Sep;113(3):704-12. doi: 10.1097/ALN.0b013e3181ed098d. Review. No abstract available.

PMID:
20693871
2.

Thalidomide, an antiangiogenic agent with clinical activity in cancer.

Ng SS, Brown M, Figg WD.

Biomed Pharmacother. 2002 Jun;56(4):194-9. Review.

PMID:
12109812
3.

Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.

Kelland L.

Curr Opin Mol Ther. 2007 Feb;9(1):86-91.

PMID:
17330406
4.

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.

Roukos DH, Tzakos A, Zografos G.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116. No abstract available. Erratum in: Expert Rev Anticancer Ther. 2009 Nov;9(11):1700.

PMID:
19828000
5.

Combining radiotherapy and angiogenesis inhibitors: clinical trial design.

Citrin D, Ménard C, Camphausen K.

Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):15-25.

PMID:
16377411
6.

Antiangiogenic therapy at a crossroads: clinical trial results and future directions.

Ellis LM.

J Clin Oncol. 2003 Dec 1;21(23 Suppl):281s-283s. No abstract available.

PMID:
14645411
7.

Angiogenesis inhibitors in cancer therapy.

Dredge K, Dalgleish AG, Marriott JB.

Curr Opin Investig Drugs. 2003 Jun;4(6):667-74. Review.

PMID:
12901224
8.

Angiogenesis: new opportunities and solutions for drug development. Predictive markers for antiangiogenic drugs.

Gerber HP.

Expert Opin Investig Drugs. 2003 Dec;12(12):2001-4. No abstract available.

PMID:
14640944
9.

Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology.

Verhoef C, de Wilt JH, Verheul HM.

Curr Pharm Des. 2006;12(21):2623-30. Review.

PMID:
16842162
10.
11.

Clinical aspects of natural anti-angiogenic drugs.

Neal CP, Berry DP, Doucas H, Manson MM, Steward W, Garcea G.

Curr Drug Targets. 2006 Mar;7(3):371-83. Review.

PMID:
16555420
12.

Angiogenesis: a potential target for therapy of soft tissue sarcomas.

Hoekman K, Pinedo HM.

Cancer Treat Res. 2004;120:169-80. Review. No abstract available.

PMID:
15217224
13.

Retinal anti-angiogenesis by a new route.

Bicknell R.

Nat Biotechnol. 2008 May;26(5):528-9. doi: 10.1038/nbt0508-528. No abstract available.

PMID:
18464784
14.

The therapeutic potential of novel antiangiogenic therapies.

Scappaticci FA.

Expert Opin Investig Drugs. 2003 Jun;12(6):923-32. Review.

PMID:
12783597
15.

Antiangiogenic strategies and agents in clinical trials.

Rosen L.

Oncologist. 2000;5 Suppl 1:20-7. Review.

16.
17.

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.

van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, Remick SC.

Curr Opin Hematol. 2007 Sep;14(5):468-80. Review.

PMID:
17934353
18.

Angiogenesis and cancer: recent advances.

Cáceres W, González S.

P R Health Sci J. 2003 Jun;22(2):149-51. Review.

PMID:
12866139
19.

Molecular and cellular biomarkers for angiogenesis in clinical oncology.

Bertolini F, Mancuso P, Shaked Y, Kerbel RS.

Drug Discov Today. 2007 Oct;12(19-20):806-12. Epub 2007 Sep 27. Review.

PMID:
17933680
20.

Roche consolidates grip on anti-angiogenesis market.

Moran N.

Nat Biotechnol. 2008 Oct;26(10):1055-6. doi: 10.1038/nbt1008-1055. No abstract available.

PMID:
18846054

Supplemental Content

Support Center